One-Dose bone shield for HIV patients? new trial tests zoledronic acid

NCT ID NCT06762730

Recruiting now Prevention Sponsor: Hadassah Medical Organization Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether one dose of zoledronic acid can prevent bone loss that often happens when people start HIV medications. About 110 adults newly diagnosed with HIV and showing early bone thinning will be randomly assigned to get the drug or just follow-up. Researchers will track bone density over 48 months to see if the single dose protects bone mass.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zoledronic acid
What this could lead to: If it works, this could offer a simple, one-time way to protect bone health in people starting HIV therapy.
What could go wrong: This is a Phase 4 trial with only 110 participants, so results may not apply to everyone. The drug may not prevent bone loss as hoped, and side effects like jaw problems or atypical fractures are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-INFECTED INDIVIDUALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-INFECTED INDIVIDUALS OSTEOPENIA

Contacts and locations

Locations

Hadassah Hebrew University Medical Center
RECRUITING

Jerusalem, 9112001, Israel
Rambam Medical Center
NOT_YET_RECRUITING

Haifa, Israel
Sheba Medical Center
NOT_YET_RECRUITING

Ramat Gan, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.